159 related articles for article (PubMed ID: 29152307)
1. Coagulation profile of Sudanese children with homozygous sickle cell disease and the effect of treatment with omega-3 fatty acid on the coagulation parameters.
Awoda S; Daak AA; Husain NE; Ghebremeskel K; Elbashir MI
BMC Hematol; 2017; 17():18. PubMed ID: 29152307
[TBL] [Abstract][Full Text] [Related]
2. Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
Daak AA; Elderdery AY; Elbashir LM; Mariniello K; Mills J; Scarlett G; Elbashir MI; Ghebremeskel K
Blood Cells Mol Dis; 2015 Jun; 55(1):48-55. PubMed ID: 25976467
[TBL] [Abstract][Full Text] [Related]
3. Abnormality of erythrocyte membrane n-3 long chain polyunsaturated fatty acids in sickle cell haemoglobin C (HbSC) disease is not as remarkable as in sickle cell anaemia (HbSS).
Ren H; Ghebremeskel K; Okpala I; Ugochukwu CC; Crawford M; Ibegbulam O
Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):1-6. PubMed ID: 16314081
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
6. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
7. Combined hydroxyurea and ET
Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
[TBL] [Abstract][Full Text] [Related]
8. Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids.
Ren H; Obike I; Okpala I; Ghebremeskel K; Ugochukwu C; Crawford M
Prostaglandins Leukot Essent Fatty Acids; 2005 Jun; 72(6):415-21. PubMed ID: 15876528
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.
Setty BNY; Betal SG; Miller RE; Brown DS; Meier M; Cahill M; Lerner NB; Apollonsky N; Stuart MJ
Prostaglandins Leukot Essent Fatty Acids; 2019 Jul; 146():11-18. PubMed ID: 31186149
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state.
Buseri FI; Jeremiah ZA; Shokunbi WA
Hematology; 2006 Oct; 11(5):375-9. PubMed ID: 17607590
[TBL] [Abstract][Full Text] [Related]
11. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
12. Relevance of fibrinolytic protein (D-dimer) and fibrinopeptide A as markers of sickle cell anaemia vaso-occlusive crisis.
Ekwere TA; Ebele U; Ekanem M; Ogunro PS
Niger Postgrad Med J; 2014 Sep; 21(3):225-30. PubMed ID: 25331238
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes.
Nahavandi M; Tavakkoli F; Millis RM; Wyche MQ; Habib MJ; Tavakoli N
Hematology; 2006 Aug; 11(4):291-4. PubMed ID: 17178670
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of hypercoagulability change in steady state and during vaso-occlusive crisis among Sudanese patients living with sickle cell disease.
Mohamed EA; Elgari MM; Babker AM; Waggiallah HA
Afr Health Sci; 2020 Mar; 20(1):392-396. PubMed ID: 33402927
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease.
Daak AA; Lopez-Toledano MA; Heeney MM
Complement Ther Med; 2020 Aug; 52():102482. PubMed ID: 32951732
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Tavakkoli F; Nahavandi M; Wyche MQ; Perlin E
Hematology; 2004 Feb; 9(1):61-4. PubMed ID: 14965870
[TBL] [Abstract][Full Text] [Related]
17. Dental Caries in Children with Sickle Cell Disease and Its Association with the Use of Hydroxyurea and Penicillin Prophylaxis in Dar Es Salaam.
Minja IK; Wilson EM; Machibya FM; Jonathan A; Cornel F; Ruggajo P; Makani J; Balandya E
Pediatric Health Med Ther; 2024; 15():121-128. PubMed ID: 38533196
[TBL] [Abstract][Full Text] [Related]
18. Patients with sickle cell disease have reduced blood antioxidant protection.
Ren H; Ghebremeskel K; Okpala I; Lee A; Ibegbulam O; Crawford M
Int J Vitam Nutr Res; 2008 May; 78(3):139-47. PubMed ID: 19003736
[TBL] [Abstract][Full Text] [Related]
19. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.
Tantawy AA; Adly AA; Ismail EA; Habeeb NM; Farouk A
Platelets; 2013; 24(8):605-14. PubMed ID: 23249216
[TBL] [Abstract][Full Text] [Related]
20. Hematological parameters in Ghanaian sickle cell disease patients.
Antwi-Boasiako C; Ekem I; Abdul-Rahman M; Sey F; Doku A; Dzudzor B; Dankwah GB; Otu KH; Ahenkorah J; Aryee R
J Blood Med; 2018; 9():203-209. PubMed ID: 30464671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
